BioCentury
ARTICLE | Product Development

Fresh $20M allows Azura to move lead candidate into pivotal testing for major cause of dry eye

Registrational study to start in 1Q21 in Australia, New Zealand

October 23, 2020 11:54 PM UTC

With a new $20 million financing that doubles what the company has raised to date, Israel’s Azura will be able to advance its lead program into a registrational study to address a major cause of dry eye syndrome.

Azura Ophthalmics Ltd. received the funding from current shareholders OrbiMed Advisors, TPG Biotech, Brandon Capital’s Medical Research Commercialisation Fund and Ganot Capital. Azura CEO Marc Gleeson told BioCentury that the company has now raised $38.4 million since its founding in 2014...

BCIQ Company Profiles

Azura Ophthalmics Ltd.